Targeting Androgen Receptor in Breast Cancer: Enzalutamide as a Novel Breast Cancer Therapeutic
Technical Report,15 Aug 2014,14 Aug 2015
Regents of the University of Colorado Aurora United States
Pagination or Media Count:
Enzalutamide has clinical activity in breast cancer as a single agent and in combination with exemestane. Activity is seen in both triple negative AR positive BC and also ER positive AR positive BC. Clinical data in Her2 positive AR positive BC is too immature to make conclusions. The proposed clinical trials for Years 3-5 appear to be justified based on clinical activity and the current preclinical data.